Related references
Note: Only part of the references are listed.NAFLD between genes and environment: what drives fibrogenesis?
Angelo Armandi et al.
GUT (2021)
Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)
Menso J. Westerouen Van Meeteren et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis
Feng Liu et al.
HEPATOLOGY (2020)
Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany
Christian Labenz et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Prof Jorn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH)
Joern M. Schattenberg
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
Rod S. Taylor et al.
GASTROENTEROLOGY (2020)
Therapeutic landscape for NAFLD in 2020
Brent A. Neuschwander-Tetri
GASTROENTEROLOGY (2020)
Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?
Nadine Gehrke et al.
GASTROENTEROLOGY (2020)
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter et al.
GASTROENTEROLOGY (2020)
Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease
Donghee Kim et al.
HEPATOLOGY (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
Guadalupe Garcia-Tsao et al.
JOURNAL OF HEPATOLOGY (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis
Bjorn Carlsson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum
Oliver Glass et al.
JOURNAL OF HEPATOLOGY (2020)
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation
Jamie Bates et al.
JOURNAL OF HEPATOLOGY (2020)
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2020)
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2020)
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Beth A. Davison et al.
JOURNAL OF HEPATOLOGY (2020)
On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis
Joern M. Schattenberg et al.
JOURNAL OF HEPATOLOGY (2020)
A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage
Michal Segal-Salto et al.
JHEP REPORTS (2020)
Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application
Dicky Struik et al.
CURRENT OPINION IN LIPIDOLOGY (2019)
Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease
Katharina Staufer et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram
Yu-Jie Zhou et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH
Rohit Loomba et al.
HEPATOLOGY (2019)
Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis
Yoshio Sumida et al.
HEPATOLOGY RESEARCH (2019)
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
David E. Kleiner et al.
JAMA NETWORK OPEN (2019)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
Acetyl-CoA carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
Eric J. Lawitz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2018)
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
Mohammad Shadab Siddiqui et al.
HEPATOLOGY (2018)
JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study
A. M. Diehl et al.
JOURNAL OF HEPATOLOGY (2018)
Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study
V. Ratziu et al.
JOURNAL OF HEPATOLOGY (2018)
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Vlad Ratziu
JOURNAL OF HEPATOLOGY (2018)
Functional Gut Microbiota Remodeling Contributes to the Caloric Restriction-Induced Metabolic Improvements
Salvatore Fabbiano et al.
CELL METABOLISM (2018)
Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany
Christian Labenz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
Dietary Saturated Fat Promotes Development of Hepatic Inflammation Through Toll-Like Receptor 4 in Mice
Alton G. Sutter et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors
Nadine Gehrke et al.
JOURNAL OF HEPATOLOGY (2016)
Hepatic TLR4 signaling in obese NAFLD
Torfay Sharifnia et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2015)
Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis
Mustafa Cengiz et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
UDCA for NASH: End of the story?
Marion Haedrich et al.
JOURNAL OF HEPATOLOGY (2011)
TLR4 links innate immunity and fatty acid-induced insulin resistance
Hang Shi et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Share Paper
